iSpecimen to Report Second Quarter 2024 Results on August 6, 2024
iSpecimen Inc. (Nasdaq: ISPC), an online global marketplace connecting scientists with biospecimen providers for medical research, has announced its plans to report second quarter 2024 financial results on August 6, 2024, before the market opens. The company will host a conference call and audio webcast at 8:30 a.m. Eastern Time, featuring remarks by CEO Tracy Curley.
Interested parties can join the live call at +1-800-717-1738 (U.S. Toll Free) or +1-646-307-1865 (International). A webcast will be available, and a replay of the call will be accessible until August 20, 2024. The earnings report and subsequent call may provide insights into iSpecimen's financial performance and future outlook.
iSpecimen Inc. (Nasdaq: ISPC), un mercato globale online che mette in contatto scienziati con fornitori di biospecimen per la ricerca medica, ha annunciato i suoi piani per riportare i risultati finanziari del secondo trimestre 2024 il 6 agosto 2024, prima dell'apertura del mercato. L'azienda ospiterà una conferenza telefonica e una webcast audio alle 8:30 ora orientale, con interventi del CEO Tracy Curley.
Le parti interessate possono unirsi alla chiamata dal vivo al +1-800-717-1738 (numero verde USA) o al +1-646-307-1865 (internazionale). Sarà disponibile una webcast, e una registrazione della chiamata sarà accessibile fino al 20 agosto 2024. Il rapporto sugli utili e la successiva chiamata potrebbero fornire approfondimenti sulle performance finanziarie di iSpecimen e sulle prospettive future.
iSpecimen Inc. (Nasdaq: ISPC), un mercado global en línea que conecta a científicos con proveedores de biospecimen para la investigación médica, ha anunciado sus planes para informar sobre los resultados financieros del segundo trimestre de 2024 el 6 de agosto de 2024, antes de la apertura del mercado. La empresa llevará a cabo una conferencia telefónica y una transmisión de audio a las 8:30 a.m. hora del Este, con comentarios del CEO Tracy Curley.
Las partes interesadas pueden unirse a la llamada en vivo al +1-800-717-1738 (número gratuito en EE. UU.) o al +1-646-307-1865 (internacional). Habrá una transmisión disponible, y se podrá acceder a una grabación de la llamada hasta el 20 de agosto de 2024. El informe de ganancias y la llamada posterior pueden ofrecer información sobre el desempeño financiero de iSpecimen y perspectivas futuras.
iSpecimen Inc. (Nasdaq: ISPC)는 의학 연구를 위한 생물 샘플 제공자와 과학자들을 연결하는 글로벌 온라인 마켓플레이스이며, 2024년 2분기 재무 결과를 2024년 8월 6일 시장 개장 전에 발표할 계획을 발표했습니다. 회사는 동부 표준시 기준으로 오전 8시 30분에 CEO Tracy Curley의 발언을 포함한 전화 회의 및 오디오 웹캐스트를 개최할 예정입니다.
관심 있는 분들은 +1-800-717-1738 (미국 무료번호) 또는 +1-646-307-1865 (국제 전용)로 생방송에 참여할 수 있습니다. 웹캐스트가 제공될 예정이며, 통화 녹음은 2024년 8월 20일까지 접근 가능합니다. 수익 보고서와 이후의 통화는 iSpecimen의 재무 성과와 미래 전망에 대한 통찰력을 제공할 수 있습니다.
iSpecimen Inc. (Nasdaq: ISPC), un marché mondial en ligne qui connecte les scientifiques aux fournisseurs de biospecimens pour la recherche médicale, a annoncé son intention de publier les résultats financiers du deuxième trimestre 2024 le 6 août 2024, avant l'ouverture du marché. L'entreprise organisera une conférence téléphonique et un webinaire audio à 8h30, heure de l'Est, avec des interventions du PDG Tracy Curley.
Les parties intéressées peuvent participer à l'appel en direct au +1-800-717-1738 (numéro gratuit aux États-Unis) ou au +1-646-307-1865 (international). Un webinaire sera disponible, et un enregistrement de l'appel sera accessible jusqu'au 20 août 2024. Le rapport sur les bénéfices et l'appel qui suivra pourraient fournir des informations sur la performance financière d'iSpecimen et les perspectives d'avenir.
iSpecimen Inc. (Nasdaq: ISPC), ein weltweiter Online-Marktplatz, der Wissenschaftler mit Anbietern von biologischen Proben für die medizinische Forschung verbindet, hat angekündigt, die Finanzergebnisse für das zweite Quartal 2024 am 6. August 2024 vor Marktöffnung zu berichten. Das Unternehmen wird um 8:30 Uhr Eastern Time eine Telefonkonferenz und eine Audio-Webcast abhalten, in der CEO Tracy Curley zu Wort kommt.
Interessierte Parteien können unter +1-800-717-1738 (US-Hotline) oder +1-646-307-1865 (international) an dem Live-Anruf teilnehmen. Eine Webcast wird verfügbar sein, und eine Wiederholung des Anrufs wird bis zum 20. August 2024 zugänglich sein. Der Bericht über die Erträge und der anschließende Anruf könnten Einblicke in die finanzielle Performance von iSpecimen und die zukünftige Perspektive geben.
- None.
- None.
LEXINGTON, Mass., July 25, 2024 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, today announced that it will report its financial results for the second quarter ended June 30, 2024, before the market opens on Tuesday, August 6, 2024.
The Company will host a conference call and audio webcast that morning at 8:30 a.m. Eastern Time featuring remarks by Tracy Curley, CEO.
| Event: | iSpecimen Second Quarter 2024 Results Conference Call |
| Date: | Tuesday, August 6, 2024 |
| Time: | 8:30 a.m. Eastern Time |
| Live Call: | +1-800-717-1738 (U.S. Toll Free) or +1-646-307-1865 (International) |
| Webcast: | https://viavid.webcasts.com/starthere.jsp?ei=1680345&tp_key=2f4ff16577 |
For interested individuals unable to join the conference call, a replay will be available through August 20, 2024, at +1-844-512-2921 (U.S. Toll Free) or +1-412-317-6671 (International). Participants must use the following code to access the replay of the call: 1170973. An archived version of the webcast will also be available on iSpecimen’s Investor Relations site: https://investors.ispecimen.com/presentations/.
About iSpecimen
iSpecimen (Nasdaq: ISPC) offers an online marketplace for human biospecimens, connecting scientists in commercial and non-profit organizations with healthcare providers that have access to patients and specimens needed for medical discovery. Proprietary, cloud-based technology enables scientists to intuitively search for specimens and patients across a federated partner network of hospitals, labs, biobanks, blood centers and other healthcare organizations. For more information, please visit www.ispecimen.com.
Forward Looking Statements
This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements are characterized by future or conditional verbs such as “may,” “will,” “expect,” “intend,” “anticipate,” “believe,” “estimate,” “continue” or similar words. You should read statements that contain these words carefully because they discuss future expectations and plans, which contain projections of future results of operations or financial condition or state other forward-looking information.
Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to the risk factors contained in the Company’s filings with the U.S. Securities and Exchange Commission, which are available for review at www.sec.gov. Forward-looking statements speak only as of the date they are made. New risks and uncertainties arise over time, and it is not possible for the Company to predict those events or how they may affect the Company. If a change to the events and circumstances reflected in the Company’s forward-looking statements occurs, the Company’s business, financial condition and operating results may vary materially from those expressed in the Company’s forward-looking statements.
Readers are cautioned not to put undue reliance on forward-looking statements, and the Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.
For further information, please contact:
Investor Contact
KCSA Strategic Communications
Phil Carlson
212-896-1233
iSpecimen@kcsa.com
FAQ
When will iSpecimen (ISPC) report its Q2 2024 financial results?
What time is iSpecimen's (ISPC) Q2 2024 earnings conference call?
How can I access iSpecimen's (ISPC) Q2 2024 earnings call?
Until when will the replay of iSpecimen's (ISPC) Q2 2024 earnings call be available?
